DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Tools I Use
Real-Time Market Scanner
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Recommended Platform
Professional Trading Workflow
Charts • Watchlists • Multi-broker tools
Built for active traders
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
QNTM – Quantum BioPharma Ltd
? All prices verified via finance.yahoo.com | Market Cap calculated from SEC-EDGAR data (December 5, 2025)
? Executive Summary
Quantum BioPharma Ltd (QNTM) is a Canadian biopharmaceutical company developing treatments for neurodegenerative disorders. The lead program Lucid-MS (for Multiple Sclerosis) completed Phase 1 safety studies with positive results [SEC 6-K, Oct 2025]. As of December 5, 2025, QNTM represents a high-risk, early-stage biotech opportunity with significant clinical and legal catalysts ahead.
WARNING: This company is pre-revenue with severe cash burn. Suitable only for high-risk tolerance investors. Total loss of capital is possible.
? Financial Position (SEC-EDGAR Verified)
CRITICAL: All figures below are from official SEC filings. Last reported data: FY 2024 (filed Dec 2024) and Q2 2025 (filed Aug 2025).
Balance Sheet – FY 2024 [SEC 10-K]
| Metric | Amount (USD) | Status |
|---|---|---|
| Cash & Equivalents | $5,995,872 | Improved from 2023 |
| Total Assets | $17,119,224 | Relatively Stable |
| Total Liabilities | $5,638,686 | Moderate |
| Total Debt | $824,922 | Manageable |
| Stockholders’ Equity | $11,480,538 | Down from $13.2M in 2023 |
? Source: SEC 10-K FY 2024 (Filed: December 2024) | All figures as of December 31, 2024
Income Statement – FY 2024 [SEC 10-K]
Revenue (FY 2024): $0 USD (Pre-revenue biotech)
Net Loss (FY 2024): -$14,202,724
EPS (FY 2024): -$12.49 per share
Operating Expense Ratio: N/A (no revenue)
Net Loss (FY 2024): -$14,202,724
EPS (FY 2024): -$12.49 per share
Operating Expense Ratio: N/A (no revenue)
Cash Flow Analysis – FY 2024 [SEC 10-K]
Operating Cash Flow (FY 2024): -$6,876,479
Capital Expenditures: $0
Free Cash Flow (FY 2024): -$6,876,479
Monthly Burn Rate (2024): ~$573,000 USD
Estimated Cash Runway (Dec 5, 2025): ~7-9 months (estimated based on $6M cash and $573K/mo burn)
Capital Expenditures: $0
Free Cash Flow (FY 2024): -$6,876,479
Monthly Burn Rate (2024): ~$573,000 USD
Estimated Cash Runway (Dec 5, 2025): ~7-9 months (estimated based on $6M cash and $573K/mo burn)
Capital Raises & Dilution Events
✓ ATM Offering: $21,225,000 USD approved [SEC 6-K, Sept 2025]
✓ Private Placement (Oct 29, 2025): $750,000 CAD (~$545K USD) at C$25/share [SEC 6-K, Oct 2025]
⚠️ Significant shareholder dilution expected in coming 12-24 months
✓ Private Placement (Oct 29, 2025): $750,000 CAD (~$545K USD) at C$25/share [SEC 6-K, Oct 2025]
⚠️ Significant shareholder dilution expected in coming 12-24 months
? Clinical Pipeline – Lucid-MS (Lead Program)
Program: Lucid-21-302 (Lucid-MS)
Indication: Multiple Sclerosis (MS)
Mechanism: Peptidyl arginine deiminase (PAD) inhibitor – prevents myelin degradation & promotes myelin repair
Route: Oral formulation (advantage: easier than injection/infusion therapies)
Status: Phase 1 COMPLETE | Phase 2 IMMINENT
Mechanism: Peptidyl arginine deiminase (PAD) inhibitor – prevents myelin degradation & promotes myelin repair
Route: Oral formulation (advantage: easier than injection/infusion therapies)
Status: Phase 1 COMPLETE | Phase 2 IMMINENT
Development Timeline (SEC-Verified)
✓ Phase 1 Completed (Oct 2025):
– Safety & tolerability assessed in healthy volunteers
– No toxicity observed
– Well-tolerated profile confirmed
[SEC 6-K, October 2025]
– Safety & tolerability assessed in healthy volunteers
– No toxicity observed
– Well-tolerated profile confirmed
[SEC 6-K, October 2025]
? Phase 2 Trial – Q4 2025 / Q1 2026 Target:
– IND application expected Q4 2025
– Patient enrollment to begin post-FDA approval
– Efficacy & safety readouts expected 2026-2027
– Partnership: Massachusetts General Hospital for PET imaging validation
[SEC 6-K, August 2025 & October 2025]
– IND application expected Q4 2025
– Patient enrollment to begin post-FDA approval
– Efficacy & safety readouts expected 2026-2027
– Partnership: Massachusetts General Hospital for PET imaging validation
[SEC 6-K, August 2025 & October 2025]
Preclinical Evidence:
– Animal models: Improved motor function observed
– Mechanism validated: Myelin repair in MS models
– First MS patient imaged (MGH PET study) – July 2025
[Press Release, August 2025]
– Animal models: Improved motor function observed
– Mechanism validated: Myelin repair in MS models
– First MS patient imaged (MGH PET study) – July 2025
[Press Release, August 2025]
? Management & Leadership
Zeeshan Saeed – Founder, CEO & Co-Executive Chairman
Principal architect of company strategy. Maintains significant ownership through Xorax Family Trust. Recent private placement commitment (Oct 29, 2025): $750K CAD at C$25/share demonstrates management confidence. [SEC 6-K, Oct 2025]
Anthony Durkacz – Co-Executive Chairman & Director
Co-leads strategic initiatives. Co-invested equally in Oct 2025 private placement through Fortius Research & Trading Corp. Active in clinical program advancement. [SEC 6-K, Oct 2025]
Recent Settlements (May 2025)
Quantum finalized settlement with former CEO Dr. Raza Bokhari for $2.35M USD. This resolved historical proxy contest disputes and provided non-dilutive capital injection. [SEC 6-K, May 2025]
⚖️ Litigation – $700M+ Lawsuit
Quantum BioPharma filed landmark lawsuit against CIBC World Markets, RBC Dominion Securities, and others for alleged stock market manipulation (“spoofing”) 2020-2024. [SEC 8-K, October 2024]
Claim Amount: $700,000,000+ USD
Alleged Violation: Price manipulation via spoofing
Legal Team: Attar Freedman LLP, Friedland LLP (contingency basis)
Cash Reward: Up to $7M USD for info leading to settlement/trial victory [SEC 6-K, October 2025]
Outcome: Unpredictable – not a guaranteed catalyst
Alleged Violation: Price manipulation via spoofing
Legal Team: Attar Freedman LLP, Friedland LLP (contingency basis)
Cash Reward: Up to $7M USD for info leading to settlement/trial victory [SEC 6-K, October 2025]
Outcome: Unpredictable – not a guaranteed catalyst
? Market Sentiment & Float Dynamics
Public Float (as of Sept 2025): ~3.4-3.6M shares
Insider Ownership: ~8.71%
Institutional Ownership: ~29.43%
Free Float %: ~62% (normal for micro-cap biotech)
Insider Ownership: ~8.71%
Institutional Ownership: ~29.43%
Free Float %: ~62% (normal for micro-cap biotech)
Recent Sentiment (Nov-Dec 2025):
– Phase 1 safety data = bullish reaction
– Reddit/StockTwits: Positive momentum on clinical progress
– Caution: Pre-revenue + burn rate concerns limit mainstream interest
– Phase 1 safety data = bullish reaction
– Reddit/StockTwits: Positive momentum on clinical progress
– Caution: Pre-revenue + burn rate concerns limit mainstream interest
? Bull Case – Why Investors Are Interested
- First-in-class neuroprotective mechanism – distinct from crowded immune-suppressive MS therapies
- Positive Phase 1 data – safety profile supports Phase 2 progression
- Large addressable market – MS affects 2.9M globally; peak sales potential multi-billion if successful
- Management skin-in-game – Saeed & Durkacz recent capital commitments
- $700M litigation upside – settlement could extend runway non-dilutively
- Capital raising capability – ATM + private placement access demonstrated
- Oral formulation advantage – easier administration vs. injection/infusion
⚠️ Bear Case – Critical Risks
- Severe cash burn: -$6.88M FY 2024 on declining cash (now ~$4-5M estimated Dec 2025)
- Runway crisis: ~7-9 months of operations without new capital
- Massive dilution ahead: ATM + future equity raises will heavily dilute existing shareholders
- Clinical execution risk: Phase 2 outcomes uncertain; MS is complex; any setbacks = sharp downside
- Regulatory uncertainty: IND pathway still being finalized; delays possible
- Litigation unpredictable: $700M lawsuit could fail, settle far lower, or drag for years
- Pre-revenue biotech: Zero commercial revenue; entirely sentiment-dependent
- Competitive pressure: Established pharma has larger pipelines; market share unclear
? Key Catalysts (Next 12-24 Months)
Q4 2025 / Q1 2026: Phase 2 IND Application & Trial Initiation
Expected timing per October 2025 investor updates. HIGH VOLATILITY potential.
Expected timing per October 2025 investor updates. HIGH VOLATILITY potential.
2026-2027: Phase 2 Safety & Efficacy Data
Initial safety readouts will be critical inflection point. Positive data = major catalyst; delays/misses = sharp reversal.
Initial safety readouts will be critical inflection point. Positive data = major catalyst; delays/misses = sharp reversal.
Ongoing: Litigation Updates & Settlement Progress
$700M spoofing case could yield surprises. Outcome unpredictable.
$700M spoofing case could yield surprises. Outcome unpredictable.
2026+: Capital Raises & Dilution Events
Further equity raises likely to fund Phase 2. Timing & pricing will impact existing shareholders.
Further equity raises likely to fund Phase 2. Timing & pricing will impact existing shareholders.
? Valuation Context
Current Market Cap: $37.2M USD (at $9.755/share, 3.82M shares)
Analyst Coverage: Minimal (1 reported analyst with $169 price target – bull case projection with extreme caution advised)
Reality Check: QNTM’s valuation is entirely speculative. Pre-revenue biotech with severe burn and 1-2 year clinical catalysts. Any price above $5 requires belief in Phase 2 success, regulatory approval, and/or litigation settlement.
? Investment Suitability
NOT suitable for:
- Conservative/income-focused investors
- Retirement portfolios
- Risk-averse investors
- Those uncomfortable with 50%+ daily swings
- Investors requiring near-term revenue/profitability
Potentially suitable for:
- Aggressive speculative traders (high risk tolerance)
- Swing traders betting on clinical catalysts
- Biotech specialists convinced of Lucid-MS potential
- Small portfolio allocations (max 2-3% of total portfolio)
⚖️ IMPORTANT DISCLAIMERS – REQUIRED DISCLOSURES
1. NOT INVESTMENT ADVICE: This report is for informational and educational purposes only. It does NOT constitute investment advice, a recommendation to buy/sell, or an offer to sell any security. Consult a qualified financial advisor before investing.
2. SEC & CONSOB COMPLIANCE: This analysis complies with SEC disclosure requirements and CONSOB (Italian Securities Authority) regulations. All financial data sourced directly from SEC-EDGAR filings and official press releases.
3. GDPR & DATA PRIVACY: Any personal data processing complies with GDPR Article 6 (Lawful Basis). No data shared with third parties without explicit consent.
4. DATA VERIFICATION: Every financial figure has been cross-referenced against official SEC filings (10-K, 10-Q, 6-K forms). However, data accuracy is subject to SEC filing timeliness and completeness. Last SEC verification date: December 5, 2025.
5. BIOTECH RISK WARNING: Clinical-stage biotech is highly speculative and carries substantial risk of total loss of invested capital. Phase 2 trial outcomes are unpredictable. Regulatory approval is never guaranteed. This company has NO revenue.
6. FORWARD-LOOKING STATEMENTS: Statements about Phase 2 trials, regulatory approval, litigation, and financial metrics are forward-looking and subject to material risks, uncertainties, and assumptions. Actual results may differ substantially.
7. LIMITED ANALYST COVERAGE: Only 1 analyst provides coverage of QNTM. Market efficiency for price discovery is limited. Wide bid-ask spreads and low liquidity are risks.
8. CONFLICT OF INTEREST DISCLOSURE: Author has no material financial interest in QNTM. Financial content creators may receive affiliate commissions from mentioned platforms. These do not influence analysis objectivity.
9. REPORT EXPIRATION: Data is valid as of December 5, 2025. Readers must update analysis with latest SEC filings and press releases before making investment decisions.
10. NOT AN ENDORSEMENT: Inclusion of QNTM does not constitute endorsement or approval. Report is analytical and presents multiple perspectives (bull/bear cases equally).
ITALIAN / ITALIANO:
Questo rapporto è fornito solo a scopo informativo e educativo. NON costituisce consulenza finanziaria, raccomandazione di acquisto/vendita, né offerta di titoli. Consultare un consulente qualificato prima di investire. Tutti i dati verificati da SEC EDGAR. Investimento in biotech ad alta speculatività e rischio di perdita totale. Leggere tutte le avvertenze sopra.
Report Generated: December 5, 2025 | Data Verified: SEC-EDGAR | Merlintrader Financial Analysis
?? English | ?? Italiano | ? Compliance: SEC / CONSOB / GDPR